{"id":"ql1604","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"QL1604 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"QL1604 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:12.427Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06789796","phase":"PHASE3","title":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-02","conditions":"Small-cell Lung Cancer","enrollment":636},{"nctId":"NCT04864782","phase":"PHASE2, PHASE3","title":"QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer","status":"TERMINATED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-09-23","conditions":"Cervical Cancer","enrollment":46},{"nctId":"NCT05801094","phase":"PHASE1","title":"A Phase I Study of QL1604 for Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-07-20","conditions":"Advanced Solid Tumor","enrollment":71},{"nctId":"NCT05649761","phase":"PHASE1","title":"A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-05-29","conditions":"Advanced Solid Tumors","enrollment":61},{"nctId":"NCT04326829","phase":"PHASE2","title":"QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-07-08","conditions":"Advanced Malignant Tumor","enrollment":86},{"nctId":"NCT05603039","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-07-01","conditions":"Advanced Liver Cancer","enrollment":80},{"nctId":"NCT04435652","phase":"PHASE2, PHASE3","title":"A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-07-01","conditions":"Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":492}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PD-1 monoclonal antibody"],"phase":"phase_3","status":"active","brandName":"QL1604","genericName":"QL1604","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"QL1604 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}